WASHINGTON, D.C. – Congressman Scott DesJarlais, M.D., a member of the House Armed Services and Agriculture Committees, released the following response to President Donald Trump’s first address to a joint session of Congress last night:
WASHINGTON, D.C. – Today, Congressman Scott DesJarlais, M.D., voted to repeal a lame-duck Obama Administration rule limiting states’ ability to drug-test unemployment insurance recipients. He said the Department of Labor rule undermines Congress’ intent for federal unemployment assistance, to ensure those re-entering the workforce are “truly able and available for work.”
WASHINGTON, D.C. – Today, the House Agriculture Committee held its first hearing of the 115th Congress to investigate “The Rural Economic Outlook,” in order to develop solutions in the next major farm bill to falling commodity prices, which could force a wave of farm closures across the country.
WASHINGTON, D.C. – At a House Armed Services Committee (HASC) hearing today, terrorism experts described the enduring threat of al Qaeda and the Islamist organization’s desire for large-scale attacks on the United States.
WASHINGTON, D.C. – Today, Congressman Scott DesJarlais, M.D., a new member of the House Armed Services Committee (HASC), received his subcommittee assignments for the 115th Congress. Rep. DesJarlais (TN-04) will serve on the Seapower and Projection Forces Subcommittee, as well as the Readiness Subcommittee.
WASHINGTON, D.C. – Congressman Scott DesJarlais, M.D., issued the following statement today, after attending the inauguration of Donald J. Trump as President of the United States:
WASHINGTON, D.C. – Congressman Scott DesJarlais issued the following statement today, after voting in the House of Representatives for a budget resolution to begin Obamacare repeal:
WASHINGTON, D.C. – On February 11, 2011, Lance Corporal Andrew Carpenter from Columbia, Tennessee, lost his life serving his country in Afghanistan. Three years prior to his tour of duty, Andrew took out a private student loan.
Washington, D.C. – CVS has announced the drug store chain will sell a generic competitor to Mylan Pharmaceutical’s EpiPen at a sixth of the price.